High Dose Vitamin D vs Standard Dose Vitamin D Study

Phase 2TerminatedNCT01988090

Mothaffar Rimawi93 enrolled

Overview

This study is being done to look at the difference, if there is a difference between two different doses of Vitamin D and the reduction of joint/muscle pain (arthralgia)that is caused by taking anti-estrogen medications (aromatase inhibitors) by breast cancer patients. The investigators hope to learn if taking a higher dose of Vitamin D is a good way to prevent aromatase inhibitor arthralgia (AIA).

Treatments with anti-estrogen agents for hormone receptor positive breast cancer is the most efficacious of systemic therapies, with aromatase inhibitors (AI's) being considered the most active anti-estrogen therapy in early stage breast cancer. But, use of these treatments has been shown to cause musculoskeletal (joint/muscle) side effects that sometimes cause patients to discontinue the use of them. Also, Vitamin D deficiency is a well know cause of a wide array of musculoskeletal issues. There is evidence that Vitamin D supplementation may help prevent arthralgia while on AI's. Therefore, the investigators want to see if giving a higher dose of Vitamin D could decrease the incidence of AIA as compared to a standard dose of Vitamin D. The investigators believe that this could possibly result in patients continued treatment with AI therapy for hormone receptor positive breast cancer.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Breast Cancer

Interventions

800 IU Vitamin D SupplementDRUG

Standard Dose

50,000 IU Vitamin D supplementDRUG

High Dose

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All participants must be female and at least 21 years of age * Signed informed consent * Patients must have had histologically confirmed stage I-III breast carcinoma that is positive for Estrogen Receptor (ER) and/or Progesterone Receptor (PR). * Post-menopausal * Beginning adjuvant aromatase inhibitor therapy, with no previous use within the last 6 weeks * Bisphosphonates are allowed at the treating investigator¡¦s discretion * Performance status (WHO/ECOG scale) 0-2. Exclusion Criteria: * History of kidney stones * Hypercalcemia at baseline, defined as any corrected calcium greater than the laboratory's normal parameters * History of either symptomatic hypercalcemia or hyperparathyroidism, at the treating investigator's discretion * Baseline Vitamin D level greater than 50 ng/mL * Inability or unwillingness to comply with, or follow study procedures. * Currently taking Phenytoin or phenobarbital -7 Currently taking cholestyramine or orlistat * Malabsorption syndrome, such as Crohn's disease Prohibited Therapies: Patients may not take additional Calcium and Vitamin D aside from the study medications. Patients who are on cholestyramine or orlistat will not be allowed on the trial. Also, patients who are taking phenytoin or phenobarbital are not allowed on the trial either because of interaction between Vitamin D and anti-epileptic medications.

Locations (2)

Washington University / Siteman Cancer Center

St Louis, Missouri, United States

Baylor College of Medicine

Houston, Texas, United States

Outcomes

Primary Outcomes

Number of Participants With Aromatase Inhibitor Induced Arthralgia (AIA) After 12 Weeks of Therapy

Aromatase Inhibitor Arthralgia (AIA) was assessed by a questionnaire that describe the level of pain experienced by the participant. The questionnaire asks 20 questions scored 0-3 in 8 categories of functioning: dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. An average composite score on the HAQ-II was calculated. The visual analog scale is the other major component of the HAQ-II, which we ask patients to mark where their pain lies on a horizontal line and we converts the number into a score from 0 to 3. For the purposes of this study, AIA will be defined as any of the following criteria: 1) increase in HAQ-II score from baseline by 0.2 or greater; or 2) increase in visual analog pain score by 0.3 or greater.

Time frame: 12 weeks

Secondary Outcomes

Compliance With Anti-Cancer Treatment

We checked compliance of aromatase inhibitor therapy during the study by reviewing the patient's use of AI drug. This will be done by counting remaining pills in patient's bottles of AI at 52 weeks. A percentage of the number of pills were actually taken of the number of pills should be taken was calculated.

Time frame: 52 Weeks

Association Between Vitamin D Levels Changes and Treatment.

Patients' serum 25-hydroxyvitamin D level were tested at baseline and week 12. The changes between baseline and week 12 were calculated.

Time frame: 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.